Evidence map›Paper›PMID 40428129›Full record

ArticleBioengineering (Basel, Switzerland)2025

In Vivo Evaluation of the Anti-Skin-Ageing Bioactivity of a Recombinant Dual Humanised Collagen and Poly-L-Lactic Acid.

Mingjie Tong, Xin Zhou, Jiongni Zhong, Dengjian Qu, Wei Chen, Chun Chen, Yiting Wang, Yaoping Liu, Shaochuan Li, Yuan Xiao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mingjie TongInstitute of Biomedicine and National Engineering Research Center of Genetic Medicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
Xin ZhouInstitute of Biomedicine and National Engineering Research Center of Genetic Medicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
Jiongni ZhongInstitute of Biomedicine and National Engineering Research Center of Genetic Medicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
Dengjian QuInstitute of Biomedicine and National Engineering Research Center of Genetic Medicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
Wei ChenGuangzhou Huike Biotech Co., Ltd., Guangzhou 510530, China.
Chun ChenInstitute of Biomedicine and National Engineering Research Center of Genetic Medicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
Yiting WangInstitute of Biomedicine and National Engineering Research Center of Genetic Medicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
Yaoping LiuGuangzhou Cheer-Derm Biotech Co., Ltd., Guangzhou 510530, China.
Shaochuan LiCollege of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.ORCID 0009-0006-5299-4539
Yuan XiaoGuangdong Marubi Biotech Co., Ltd., Guangzhou 510530, China.
Ning WangGuangdong Marubi Biotech Co., Ltd., Guangzhou 510530, China.
Chaowan GuoGuangdong Marubi Biotech Co., Ltd., Guangzhou 510530, China.ORCID 0000-0002-0555-4542
Qiuling XieInstitute of Biomedicine and National Engineering Research Center of Genetic Medicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.ORCID 0000-0002-0225-0260
Sheng XiongInstitute of Biomedicine and National Engineering Research Center of Genetic Medicine, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.

Funding

National Key Research and Development Program of China 2024YFC3406900the Key Areas Research and Development Programs' Green biomanufacturing' of Guangdong Provincial Department of Science and Technology 2022B1111070007
6 · The paper itself

Abstract

This study introduces a novel recombinant humanised collagen (DuCol) developed through codon optimisation and prokaryotic soluble expression, exhibiting exceptional biocompatibility and bioactivity. Structural integrity was confirmed via RP-HPLC, SEM, and CD spectroscopy. In vitro evaluations revealed DuCol's dose-dependent enhancement of NIH-3T3 fibroblast proliferation, adhesion, and migration. In a D-galactose-induced ageing rat model, subcutaneous implantation of DuCol showcased time-dependent anti-ageing effects. Early-stage intervention (30 days post-injection) markedly upregulated COL1A1 expression through the TGF-β/Smad3 pathway activation, outperforming poly-l-lactic acid (PLLA) in collagen deposition. Histological analysis revealed 23.4% greater dermal thickness in DuCol-treated groups compared to PLLA at 90 days. While PLLA exhibited sustained collagen stimulation beyond 90 days, DuCol exhibited superior early-phase efficacy (

Indexed as

injectable biomaterialsPLLArecombinant collagenskin ageingTGF-β signalling

Identifiers

PMID40428129
PMCPMC12109386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.